Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Standardized molecular pathology workflow for ctDNA-based ESR1 testing in HR+/HER2- metastatic breast cancer.
Guerini-Rocco E, Venetis K, Cursano G, Mane E, Frascarelli C, Pepe F, Negrelli M, Olmeda E, Vacirca D, Ranghiero A, Trapani D, Criscitiello C, Curigliano G, Rolfo C, Malapelle U, Fusco N. Guerini-Rocco E, et al. Among authors: cursano g. Crit Rev Oncol Hematol. 2024 Sep;201:104427. doi: 10.1016/j.critrevonc.2024.104427. Epub 2024 Jun 23. Crit Rev Oncol Hematol. 2024. PMID: 38917944 Review.
Early Breast Cancer Risk Assessment: Integrating Histopathology with Artificial Intelligence.
Ivanova M, Pescia C, Trapani D, Venetis K, Frascarelli C, Mane E, Cursano G, Sajjadi E, Scatena C, Cerbelli B, d'Amati G, Porta FM, Guerini-Rocco E, Criscitiello C, Curigliano G, Fusco N. Ivanova M, et al. Among authors: cursano g. Cancers (Basel). 2024 May 23;16(11):1981. doi: 10.3390/cancers16111981. Cancers (Basel). 2024. PMID: 38893102 Free PMC article. Review.
PIK3CA testing in hormone receptor-positive/HER2-negative metastatic breast cancer: real-world data from Italian molecular pathology laboratories.
Pepe F, Venetis K, Cursano G, Frascarelli C, Pisapia P, Vacirca D, Scimone C, Rappa A, Russo G, Mane E, Pagni F, Castellano I, Troncone G, Angelis C, Curigliano G, Guerini-Rocco E, Malapelle U, Fusco N. Pepe F, et al. Among authors: cursano g. Pharmacogenomics. 2024 Feb;25(3):161-169. doi: 10.2217/pgs-2023-0238. Epub 2024 Mar 5. Pharmacogenomics. 2024. PMID: 38440825
Think "HER2" different: integrative diagnostic approaches for HER2-low breast cancer.
Marchiò C, Criscitiello C, Scatena C, Santinelli A, Graziano P, Malapelle U, Cursano G, Venetis K, Fanelli GN, Pepe F, Berrino E, Angelis C, Perrone G, Curigliano G, Fusco N. Marchiò C, et al. Among authors: cursano g. Pathologica. 2023 Dec;115(6):292-301. doi: 10.32074/1591-951X-942. Pathologica. 2023. PMID: 38180137 Free PMC article. Review.
Trop-2 as an Actionable Biomarker in Breast Cancer.
Cursano G, Frigo E, Sajjadi E, Ivanova M, Venetis K, Guerini-Rocco E, Criscitiello C, Curigliano G, Fusco N. Cursano G, et al. Curr Genomics. 2023 Nov 22;24(3):129-131. doi: 10.2174/1389202924666230726112233. Curr Genomics. 2023. PMID: 38178982 Free PMC article. No abstract available.
ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
Venetis K, Pepe F, Pescia C, Cursano G, Criscitiello C, Frascarelli C, Mane E, Russo G, Taurelli Salimbeni B, Troncone G, Guerini Rocco E, Curigliano G, Fusco N, Malapelle U. Venetis K, et al. Among authors: cursano g. Cancer Treat Rev. 2023 Dec;121:102642. doi: 10.1016/j.ctrv.2023.102642. Epub 2023 Oct 13. Cancer Treat Rev. 2023. PMID: 37864956 Review.
Standardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancer.
Ivanova M, Porta FM, D'Ercole M, Pescia C, Sajjadi E, Cursano G, De Camilli E, Pala O, Mazzarol G, Venetis K, Guerini-Rocco E, Curigliano G, Viale G, Fusco N. Ivanova M, et al. Among authors: cursano g. Virchows Arch. 2024 Jan;484(1):3-14. doi: 10.1007/s00428-023-03656-w. Epub 2023 Sep 28. Virchows Arch. 2024. PMID: 37770765 Free PMC article. Review.
Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
Fusco N, Ivanova M, Frascarelli C, Criscitiello C, Cerbelli B, Pignataro MG, Pernazza A, Sajjadi E, Venetis K, Cursano G, Pagni F, Di Bella C, Accardo M, Amato M, Amico P, Bartoli C, Bogina G, Bortesi L, Boldorini R, Bruno S, Cabibi D, Caruana P, Dainese E, De Camilli E, Dell'Anna V, Duda L, Emmanuele C, Fanelli GN, Fernandes B, Ferrara G, Gnetti L, Gurrera A, Leone G, Lucci R, Mancini C, Marangi G, Mastropasqua MG, Nibid L, Orrù S, Pastena M, Peresi M, Perracchio L, Santoro A, Vezzosi V, Zambelli C, Zuccalà V, Rizzo A, Costarelli L, Pietribiasi F, Santinelli A, Scatena C, Curigliano G, Guerini-Rocco E, Martini M, Graziano P, Castellano I, d'Amati G. Fusco N, et al. Among authors: cursano g. Crit Rev Oncol Hematol. 2023 Oct;190:104103. doi: 10.1016/j.critrevonc.2023.104103. Epub 2023 Aug 16. Crit Rev Oncol Hematol. 2023. PMID: 37595344 Review.
12 results